Exelixis Earnings Call Highlights Strong Cabo Momentum
Exelixis ((EXEL)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Exelixis’ latest earnings call struck an upbeat tone, blending solid near-term financial strength with a steadily advancing oncology pipeline. Management emphasized robust growth for flagship drug CABOMETYX, expanding margins, and significant cash reserves, while acknowledging higher discounts, a heavier tax bill, and pivotal trial risks that could inject volatility into future quarters.
Revenue climbs on CABOMETYX strength
Exelixis reported about $611 million in total revenue for Q1 2026, underscoring the company’s reliance on its cabozantinib franchise. U.S. net product revenue from the cabo portfolio rose 8% year over year to $555 million, while global franchise revenue climbed 12.5% to $764 million, with CABOMETYX contributing $552.8 million, including clinical trial sales.
Profits and cash position remain solid
Profitability stayed strong, with GAAP net income of roughly $210.5 million, translating to $0.81 basic and $0.79 diluted earnings per share. On a non‑GAAP basis, excluding about $22.3 million in stock‑based compensation, net income reached $232.8 million, and the company ended the quarter with approximately $1.4 billion in cash and marketable securities.
Market share and prescription momentum build
Commercial momentum for CABOMETYX continued, as total prescriptions increased 14% versus the prior year while the broader oral TKI market grew 7%. Management highlighted a market share gain from 44% to 47% between 2025 and Q1 2026, along with record new patient starts and the highest yet first‑line RCC share for the CABOMETYX plus nivolumab combination.
Share repurchases underscore capital return focus
The company leaned into shareholder returns, repurchasing about $430.8 million of stock during the quarter and retiring roughly 10 million shares at an average price of $42.99. Following this activity, $159.4 million remained under the existing $750 million program, and Exelixis’ board approved an additional $50 million authorization for buybacks extending into late 2027.
ZANZA advances with STELLAR-303 win and broad program
ZANZA took a central role in the pipeline story, with regulators reviewing its use with atezolizumab in later‑line colorectal cancer under the STELLAR‑303 trial. That study met one of its dual primary endpoints by cutting the risk of death by 20% in the overall intent‑to‑treat population, and ZANZA now anchors seven pivotal or near‑pivotal trials across colorectal cancer, RCC, NETs, meningioma, and adjuvant minimal residual disease settings.
Key ZANZA trials show momentum but carry risk
Enrollment trends were encouraging, with STELLAR‑311 in neuroendocrine tumors tracking ahead of initial expectations and STELLAR‑304 having completed enrollment ahead of a 2026 data readout. Even so, management cautioned that key outcomes, including a still‑immature survival endpoint in a non‑liver metastasis subgroup for STELLAR‑303 and event‑driven timing for STELLAR‑304, leave investors reliant on several pivotal upcoming data releases.
Early-stage pipeline broadens beyond cabo and ZANZA
Beyond its lead assets, Exelixis is pushing four early clinical candidates—XL309, XB010, XB628, and XB371—through Phase 1 testing. Additional discovery projects, including antibody‑drug conjugates such as DLL3‑targeting XB773, are being advanced with an eye toward building the company’s next oncology franchises once cabo and ZANZA mature.
Operating costs stable despite higher people-related spend
Operating discipline was a supporting theme, as total operating expenses slipped to approximately $359 million from $363 million a year earlier. Lower clinical trial costs helped offset rising headcount‑related expenses and stock‑based compensation, signaling some cost control even as the company funds multiple pivotal and early‑stage programs.
Rising discounts weigh on net product revenue
A key headwind emerged from higher gross‑to‑net deductions on the cabozantinib franchise, which climbed to 30.2% and reduced realized revenue from product sales. Management linked the pressure to increased use in the 340B channel, larger Medicare Part D rebates and discounts, and expanded co‑pay assistance, implying ongoing sensitivity of net sales to payer and policy dynamics.
Tax provision spikes, denting bottom line
The quarter’s tax provision jumped to about $57.2 million from $8.2 million in the prior period, driven by items recognized late last year, and this materially affected reported net income. Investors were reminded that such tax swings can meaningfully influence quarterly earnings even when underlying operating performance remains steady.
Competitive setbacks highlight combo complexity in RCC
Management also referenced a recent miss in a competitor’s triplet regimen trial in RCC, underscoring the challenges of intensifying first‑line treatment with multi‑drug combinations. They stressed that tolerability concerns and partner selection make incremental benefit harder to achieve, introducing development risk and potentially shaping how Exelixis designs and positions its own combination strategies.
External partners and trials add execution risk
Some key ZANZA programs, including collaborations with large pharma partners, depend on external decision‑making, regulatory paths, and evolving treatment standards. The company acknowledged that competition, complex trial conduct, and partner dynamics may influence timelines and outcomes, even as it seeks to maintain control over core cabozantinib and ZANZA programs.
Guidance supported by Q1 trends but near-term pressures
Exelixis reaffirmed its full‑year 2026 guidance, pointing to Q1 revenues of about $611 million, double‑digit global cabo growth, and expanding CABOMETYX prescription volume and share as evidence of durable demand. At the same time, management flagged a 30.2% cabo gross‑to‑net, stable operating expenses, solid non‑GAAP earnings, strong cash of roughly $1.4 billion, and ongoing share repurchases as key pillars supporting the outlook despite discount and tax headwinds.
Exelixis’ earnings call framed a company balancing strong commercial execution with significant clinical inflection points ahead. Investors face near‑term noise from higher discounts, taxes, and trial risk, yet the combination of a growing CABOMETYX franchise, ongoing capital returns, and a deep ZANZA‑led pipeline keeps the long‑term narrative firmly oriented toward continued growth in oncology.
